-
Chinagene Tech Initiates ZVS101e Gene Therapy Trial for Bietti’s Crystalline Dystrophy
•
Beijing-based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has announced the enrollment and dosing of the first subject in a Phase I/II clinical study for its ophthalmology gene therapy ZVS101e in Tianjin. This study marks the first potentially regulatory clinical trial for a gene therapy targeting…
-
Chinagene Tech’s ZVS101e Receives FDA IND Approval for Bietti’s Crystalline Dystrophy
•
Beijing – based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has announced obtaining Investigational New Drug (IND) approval from the US FDA for its ophthalmology gene therapy ZVS101e. The therapy is designed to treat Bietti’s crystalline dystrophy (BCD), a rare genetic eye disease. ZVS101e, a Category…
